

**Cornerstone Global Partners Inc.**  
5347 Kew Cliff Road  
West Vancouver, British Columbia  
V7W 1M3

**EARLY WARNING NEWS RELEASE**

**Vancouver, British Columbia, July 4, 2017**, Cornerstone Global Partners Inc. ("**Cornerstone**") makes the following announcement in accordance with National Instrument 62-103 *The Early Warning System and Related Take Over Bids* and National Instrument 62-104 *Take-Over Bids and Issuer Bids*. Cornerstone is controlled by Stephen Van Deventer, the Chairman and Chief Executive Officer of PreveCeutical Medical Inc., formerly Carrara Exploration Inc. (the "**Issuer**").

Cornerstone advises that on June 30, 2017, it acquired ownership and control of 9,172,100 common shares in the capital of the Issuer, at a deemed issuance price of \$0.50 per share, pursuant to an amalgamation agreement dated March 21, 2017, whereby the Issuer acquired all of the issued and outstanding shares of 1050962 B.C. Ltd., formerly PreveCeutical Medical Inc. (the "**Transaction**"). The common shares of the Issuer (the "**PreveCeutical Shares**") are listed for trading on the Canadian Securities Exchange, however, the Transaction did not occur on a stock exchange or other market that represents a published market for securities.

Immediately before the completion of the Transaction, Cornerstone did not beneficially own or control any PreveCeutical Shares. As a result of the Transaction, Cornerstone beneficially owns or controls 9,172,100 PreveCeutical Shares, representing approximately 18.72% of the currently issued and outstanding PreveCeutical Shares.

Cornerstone acquired the PreveCeutical Shares for investment purposes. However, Cornerstone will review its holdings from time to time and may, in the future, increase or decrease its ownership or control over securities of the Issuer as circumstances dictate.

Upon the completion of the Transaction, the Issuer became a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers and that markets nutraceutical products to such consumers. The Issuer has one product for sale, the CELLB9™, which is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide, obtained from Caribbean blue scorpion venom. Management of the Issuer is currently working to research and develop other health and wellness products utilizing peptides contained in Caribbean blue scorpion venom and cannabinoids (the chemical constituents of marijuana).

An early warning report will be filed under the Issuer's profile on the SEDAR website at [www.sedar.com](http://www.sedar.com). A copy of the early warning report can also be obtained from the contact below.

The Issuer's head office is located at Suite 2200, 1177 West Hastings Street, Vancouver, British Columbia, V6E 2K3.

For more information contact:

Stephen Van Deventer  
Director  
(604) 306-9669